Mitochondrial drug delivery and mitochondrial disease therapy - An approach to liposome-based delivery targeted to mitochondria

Mitochondrion

Volumn 7, Issue 1-2, 2007, Pages 63-71

  Yamada, Yuma ^a   Akita, Hidetaka ^a   Kogure, Kentaro ^a   Kamiya, Hiroyuki ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Mitochondrial drug delivery; Mitochondrial gene therapy; Mitochondrial protein therapy; Multifunctional envelope type nano device (MEND); Regulation of intramitochondrial trafficking; Transferrin and GALA system

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; CARDIOVASCULAR AGENT; CIRCULAR DNA; GALA PEPTIDE; GENE PRODUCT; HYBRID PROTEIN; LIPOPLEX; LIPOSOME; MASTOPARAN; MITOCHONDRIAL DNA; MITOCHONDRIAL TARGETING SIGNAL PEPTIDE PROTEIN; OLIGODEOXYNUCLEOTIDE; PEPTIDE DERIVATIVE; PEPTIDE NUCLEIC ACID; PLASMID DNA; PROTEIN MTS; RHO FACTOR; RIBOFLAVIN; SMALL INTERFERING RNA; SUCCINIC ACID; THIAMINE; TRANSACTIVATOR PROTEIN; UBIDECARENONE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL FUNCTION; CELL MEMBRANE TRANSPORT; CELL PROTECTION; CONTROLLED RELEASE FORMULATION; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPAIR; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG TARGETING; ENCAPSULATION; ENDOSOME; GENE MUTATION; GENETIC CODE; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MACROMOLECULE; MUTATIONAL ANALYSIS; NANOPHARMACEUTICS; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN DOMAIN; RESPIRATORY CHAIN; REVIEW; TARGET CELL;

ANIMALS; DNA, MITOCHONDRIAL; DRUG CARRIERS; GENE PRODUCTS, TAT; GENE THERAPY; HUMANS; LIPOSOMES; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MOLECULAR CHAPERONES; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE NUCLEIC ACIDS; PROTEIN TRANSPORT; RATS;

EID: 33847618832     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2006.12.003     Document Type: Review

References (64)

1. Asoh S., Ohtsu T., and Ohta S. The super anti-apoptotic factor Bcl-xFNK constructed by disturbing intramolecular polar interactions in rat Bcl-xL. J. Biol. Chem. 275 (2000) 37240-37245
2. Asoh S., Ohsawa I., Mori T., Katsura K., Hiraide T., Katayama Y., Kimura M., Ozaki D., Yamagata K., and Ohta S. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. USA 99 (2002) 17107-17112
3. Asoh S., Mori T., Nagai S., Yamagata K., Nishimaki K., Miyato Y., Shidara Y., and Ohta S. Zonal necrosis prevented by transduction of the artificial anti-death FNK protein. Cell Death Differ. 12 (2005) 384-394
4. Chen Z., Felsheim R., Wong P., Augustin L.B., Metz R., Kren B.T., and Steer C.J. Mitochondria isolated from liver contain the essential factors required for RNA/DNA oligonucleotide-targeted gene repair. Biochem. Biophys. Res. Commun. 285 (2001) 188-194
5. Chinnery P.F., and Turnbull D.M. Mitochondrial DNA mutations in the pathogenesis of human disease. Mol. Med. Today 6 (2000) 425-432
6. D'Souza G.G., Rammohan R., Cheng S.M., Torchilin V.P., and Weissig V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J. Control Release 92 (2003) 189-197
7. D'Souza G.G., Boddapati S.V., and Weissig V. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion 5 (2005) 352-358
8. Del Gaizo V., and Payne R.M. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol. Ther. 7 (2003) 720-730
9. Del Gaizo V., MacKenzie J.A., and Payne R.M. Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. 80 (2003) 170-180
10. Douglas M., and Takeda M. Nuclear genes encoding mitochondrial proteins in yeast. Trends Biochem. Sci. 10 (1985) 192-194
11. Embury J., Klein D., Pileggi A., Ribeiro M., Jayaraman S., Molano R.D., Fraker C., Kenyon N., Ricordi C., Inverardi L., and Pastori R.L. Proteins linked to a protein transduction domain efficiently transduce pancreatic islets. Diabetes 50 (2001) 1706-1713
12. Endo T., Nakayama Y., and Nakai M. Avidin fusion protein as a tool to generate a stable translocation intermediate spanning the mitochondrial membranes. J. Biochem. (Tokyo) 118 (1995) 753-759
13. Flierl A., Jackson C., Cottrell B., Murdock D., Seibel P., and Wallace D.C. Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol. Ther. 7 (2003) 550-557
14. Futaki S. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm. 245 (2002) 1-7
15. Goto Y., Nonaka I., and Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348 (1990) 651-653
16. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
17. Gupta B., Levchenko T.S., and Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57 (2005) 637-651
18. Holt I.J., Harding A.E., and Morgan-Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331 (1988) 717-719
19. Holt I.J., Harding A.E., Petty R.K., and Morgan-Hughes J.A. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am. J. Hum. Genet. 46 (1990) 428-433
20. Kagawa Y., Inoki Y., and Endo H. Gene therapy by mitochondrial transfer. Adv. Drug Deliv. Rev. 49 (2001) 107-119
21. Kakudo T., Chaki S., Futaki S., Nakase I., Akaji K., Kawakami T., Maruyama K., Kamiya H., and Harashima H. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43 (2004) 5618-5628
22. Kamiya H., Akita H., and Harashima H. Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discov. Today 8 (2003) 990-996
23. Khalil I.A., Kogure K., Akita H., and Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 58 (2006) 32-45
24. Khalil I.A., Kogure K., Futaki S., and Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 281 (2006) 3544-3551
25. Kogure K., Moriguchi R., Sasaki K., Ueno M., Futaki S., and Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J. Control Release 98 (2004) 317-323
26. Mayer A., Neupert W., and Lill R. Mitochondrial protein import: reversible binding of the presequence at the trans side of the outer membrane drives partial translocation and unfolding. Cell 80 (1995) 127-137
27. Moriguchi R., Kogure K., Akita H., Futaki S., Miyagishi M., Taira K., and Harashima H. A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. Int. J. Pharm. 301 (2005) 277-285
28. Muratovska A., Lightowlers R.N., Taylor R.W., Turnbull D.M., Smith R.A., Wilce J.A., Martin S.W., and Murphy M.P. Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucl. Acid. Res 29 (2001) 1852-1863
29. Nakamura Y., Kogure K., Yamada Y., Futaki S., and Harashima H. Significant and prolonged antisense effect of a multifunctional envelope-type nano device encapsulating antisense oligodeoxynucleotide. J. Pharm. Pharmacol. 58 (2006) 431-437
30. Newman N.J. Leber's hereditary optic neuropathy. New genetic considerations. Arch. Neurol. 50 (1993) 540-548
31. Nishikawa Y., Takahashi M., Yorifuji S., Nakamura Y., Ueno S., Tarui S., Kozuka T., and Nishimura T. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 39 (1989) 399-403
32. Oku N., Doi K., Namba Y., and Okada S. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int. J. Cancer 58 (1994) 415-419
33. Otsuka M., Niijima K., Mizuno Y., Yoshida M., Kagawa Y., and Ohta S. Marked decrease of mitochondrial DNA with multiple deletions in a patient with familial mitochondrial myopathy. Biochem. Biophys. Res. Commun. 167 (1990) 680-685
34. Owen R.I., Lewin A.P., Peel A., Wang J., Guy J., Hauswirth W.W., Stacpoole P.W., and Flotte T.R. Recombinant adeno-associated virus vector-based gene transfer for defects in oxidative metabolism. Hum. Gene Ther. 11 (2000) 2067-2078
35. Pfeiffer D.R., Gudz T.I., Novgorodov S.A., and Erdahl W.L. The peptide mastoparan is a potent facilitator of the mitochondrial permeability transition. J. Biol. Chem. 270 (1995) 4923-4932
36. Saraste M. Oxidative phosphorylation at the fin de siecle. Science 283 (1999) 1488-1493
37. Schatz G. The protein import system of mitochondria. J. Biol. Chem. 271 (1996) 31763-31766
38. Scheffler I. A century of mitochondrial research: achievements and perspectives. Mitochondrion 1 (2000) 3-31
39. Schwarze S.R., Hruska K.A., and Dowdy S.F. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol. 10 (2000) 290-295
40. Seaton B.L., and Vickery L.E. Expression of human ferredoxin in Saccharomyces cerevisiae: mitochondrial import of the protein and assembly of the [2Fe-2S] center. Arch. Biochem. Biophys. 294 (1992) 603-608
41. Seibel P., Trappe J., Villani G., Klopstock T., Papa S., and Reichmann H. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. Nucl. Acid. Res. 23 (1995) 10-17
42. Shanske S., Moraes C.T., Lombes A., Miranda A.F., Bonilla E., Lewis P., Whelan M.A., Ellsworth C.A., and DiMauro S. Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology 40 (1990) 24-28
43. Shoffner J.M., Lott M.T., Lezza A.M., Seibel P., Ballinger S.W., and Wallace D.C. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 61 (1990) 931-937
44. Shokolenko I.N., Alexeyev M.F., Robertson F.M., LeDoux S.P., and Wilson G.L. The expression of exonuclease III from E. coli in mitochondria of breast cancer cells diminishes mitochondrial DNA repair capacity and cell survival after oxidative stress. DNA Repair (Amst) 2 (2003) 471-482
45. Shokolenko I.N., Alexeyev M.F., LeDoux S.P., and Wilson G.L. TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells. DNA Repair (Amst) 4 (2005) 511-518
46. Smith R.A., Porteous C.M., Coulter C.V., and Murphy M.P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem. 263 (1999) 709-716
47. Srivastava S., and Moraes C.T. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum. Mol. Genet. 10 (2001) 3093-3099
48. Suzuki Y., Kadowaki H., Atsumi Y., Hosokawa K., Katagiri H., Kadowaki T., Oka Y., Uyama K., Mokubo A., Asahina T., et al. A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocr. J. 42 (1995) 141-145
49. Tanaka J., Nagai T., Arai H., Inui K., Yamanouchi H., Goto Y., Nonaka I., and Okada S. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. Brain Dev. 19 (1997) 262-267
50. Tanaka M., Borgeld H.J., Zhang J., Muramatsu S., Gong J.S., Yoneda M., Maruyama W., Naoi M., Ibi T., Sahashi K., Shamoto M., Fuku N., Kurata M., Yamada Y., Nishizawa K., Akao Y., Ohishi N., Miyabayashi S., Umemoto H., Muramatsu T., Furukawa K., Kikuchi A., Nakano I., Ozawa K., and Yagi K. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J. Biomed. Sci. 9 (2002) 534-541
51. Taniike M., Fukushima H., Yanagihara I., Tsukamoto H., Tanaka J., Fujimura H., Nagai T., Sano T., Yamaoka K., Inui K., et al. Mitochondrial tRNA(Ile) mutation in fatal cardiomyopathy. Biochem. Biophys. Res. Commun. 186 (1992) 47-53
52. Tranebjaerg L., Schwartz C., Eriksen H., Andreasson S., Ponjavic V., Dahl A., Stevenson R.E., May M., Arena F., Barker D., et al. A new X linked recessive deafness syndrome with blindness, dystonia, fractures, and mental deficiency is linked to Xq22. J. Med. Genet. 32 (1995) 257-263
53. Vestweber D., and Schatz G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 338 (1989) 170-172
54. Wadia J.S., and Dowdy S.F. Modulation of cellular function by TAT mediated transduction of full length proteins. Curr. Protein Pept. Sci. 4 (2003) 97-104
55. Wallace D.C. Mitochondrial diseases in man and mouse. Science 283 (1999) 1482-1488
56. Wallace D.C. A Mitochondrial paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine. Annu Rev Genet. 39 (2005) 359-407
57. Wallace D.C. The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement. Gene 354 (2005) 169-180
58. Weissig V., and Torchilin V.P. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. Adv. Drug Deliv. Rev. 49 (2001) 127-149
59. Weissig V., D'Souza G.G., and Torchilin V.P. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J. Control Release 75 (2001) 401-408
60. Weissig V., Cheng S.M.D., and 'Souza G.G. Mitochondrial pharmaceutics. Mitochondrion 3 (2004) 229-244
61. Yamada Y., Kogure K., Nakamura Y., Inoue K., Akita H., Nagatsugi F., Sasaki S., Suhara T., and Harashima H. Development of efficient packaging method of oligodeoxynucleotides by a condensed nano particle in lipid envelope structure. Biol. Pharm. Bull. 28 (2005) 1939-1942
62. Yamada Y., Shinohara Y., Kakudo T., Chaki S., Futaki S., Kamiya H., and Harashima H. Mitochondrial delivery of mastoparan with transferrin liposomes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy. Int. J. Pharm. 303 (2005) 1-7
63. Zhang C., Sriratana A., Minamikawa T., and Nagley P. Photosensitisation properties of mitochondrially localised green fluorescent protein. Biochem. Biophys. Res. Commun. 242 (1998) 390-395
64. Zimmerberg J., and Parsegian V.A. Polymer inaccessible volume changes during opening and closing of a voltage-dependent ionic channel. Nature 323 (1986) 36-39